Metraipolis › archive › dc_f684b345eabf
Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies — Europe PMC PMID:42215634
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42215634
- DOI
- 10.1038/s41433-[numero omesso]-x
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-01T04:47:46.216Z
- SHA-256 of the archived text
05fa31c13dce922c780bc328168d3df62f5fd97af9cdb5f2dddcfd8238eb71d2- Stable URL of this page
https://metraipolis.com/documento/dc_f684b345eabf
How to cite
Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies — Europe PMC PMID:42215634 — Europe PMC (en), https://europepmc.org/article/MED/42215634 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f684b345eabf (Metraipolis archive dc_f684b345eabf, sha256 05fa31c13dce922c780bc328168d3df62f5fd97af9cdb5f2dddcfd8238eb71d2)
BibTeX
@misc{dcf684b345eabf,
title = {Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies — Europe PMC PMID:42215634},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42215634},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f684b345eabf; sha256 05fa31c13dce922c780bc328168d3df62f5fd97af9cdb5f2dddcfd8238eb71d2},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42215634. Agents can read the archived copy with the MCP tool read_document.